With Cellvizio®, we open access to a new dimension. Experience the power of real-time, in vivo cellular imaging.
With Cellvizio®, we open access to a new dimension. Experience the power of real-time, in vivo cellular imaging.
Our technology enhances patient outcomes and advances healthcare globally.
ACCELERATE DIAGNOSIS
By accelerating diagnosis, we aim to prevent the progression of diseases such as cancer and accurately identify conditions such as food intolerance, ensuring timely intervention to halt disease progression and prevent associated complications.
INFORM TREATMENT
We provide real-time imaging of functional reactions, offering valuable insights for physicians to create effective treatment strategies and for drug developers to research and validate more precise therapies.
IMPROVE THERAPY
In surgical interventions, we deliver accurate and precise visualization to ensure a high level of confidence in removing cancer and verifying margins. This allows surgeons to operate with greater assurance, improving the efficacy of therapeutic procedures and patient recovery.
Our vision
Provide real-time cellular visualization
Provide real-time cellular visualization
See Cells. Change Lives.
See Cells.
Change Lives.
At Mauna Kea Technologies, we are driven by the vision of a world where every diagnosis, treatment decision, and surgical intervention is guided by real-time cellular visualization.
The Cellvizio® Platform
We believe in equipping healthcare professionals with the most advanced tools to detect and treat diseases effectively. The Cellvizio real-time in vivo cellular imaging platform uses Confocal Laser Endomicroscopy (CLE) advanced imaging technology to deliver cellular visualization virtually anywhere in the human body. The system is intuitive and easy to operate, using Confocal Miniprobes™ inserted into the working channel of standard endoscopes.
The Cellvizio® Platform
We believe in equipping healthcare professionals with the most advanced tools to detect and treat diseases effectively. The Cellvizio real-time in vivo cellular imaging platform uses Confocal Laser Endomicroscopy (CLE) advanced imaging technology to deliver cellular visualization virtually anywhere in the human body. The system is intuitive and easy to operate, using Confocal Miniprobes™ inserted into the working channel of standard endoscopes.
Our partnerships
We believe great partnerships create great opportunities.
At Mauna Kea Technologies, we leverage our advanced platform, which addresses multiple indications, to forge valuable partnerships. These collaborations enable us to commercialize our innovations effectively as well as to develop new enhanced treatments.
In our existing partnerships with industry leaders such as Johnson & Johnson, Telix Pharmaceuticals, and Tasly Pharmaceutical, we are expanding the reach of our technology. Together, we’re enhancing precision medicine in various therapeutic areas such as gastroenterology, interventional pulmonology, neurosurgery, and uro-oncology, including around breakthrough developments in robotic surgery and AI-assisted imaging.
patient procedures
clinical papers
FDA clearances, CE mark,
Category 1 CPT Codes
Clinical Value of Cellvizio®
Clinical Value of Cellvizio®
One of the things that we all appreciate is that there is going to be a miss rate with structured biopsy protocols. I am worried about that miss rate, and I try to use any technology that can help me lower the miss rate and help me provide a true picture for my patient. Cellvizio® is definitely one of those tools.
Dr. J. Samarasena, University of California, Irvine (UCI)
One of the things that we all appreciate is that there is going to be a miss rate with structured biopsy protocols. I am worried about that miss rate, and I try to use any technology that can help me lower the miss rate and help me provide a true picture for my patient. Cellvizio® is definitely one of those tools.
News
YOU MIGHT ALSO LIKE TO READ
Mauna Kea Technologies Celebrates Over 700 Procedures Performed in 18 Months at IECED-OMNI Hospital in Ecuador
Mauna Kea Technologies Announces Review of Strategic Alternatives